This week, the U.S. Food and Drug Administration approved a treatment called Rubraca (rucaparib) to treat women that carry the BRCA gene mutation. The drug is now approved for those women with advanced ovarian cancer who have been treated with two or more chemotherapies.
Oncologist Dr. Gottfried Konecny is an associate professor in hematology and oncology at the David Geffen School of Medicine at UCLA and member of UCLA’s Jonsson Comprehensive Cancer Center. His research focuses on the development of novel targeted therapies for ovarian, endometrial and breast cancers.
Dr. Konecny can discuss how two previous studies he authored and co-authored with TRIO U.S. Network helped guide the FDA to reach its decision to approve the treatment.
***
UCLA’s Jonsson Comprehensive Cancer Center has more than 450 researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation’s largest comprehensive cancer centers, the Jonsson Comprehensive Cancer Center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In August 2016, the Jonsson cancer center ranked among the top five cancer centers nationwide by U.S. News & World Report.
|
